Goldman Sachs averages +18% in industry turnover
It could indeed be a golden year for generic drug makers, according to a Goldman Sachs report. Indeed, the Healthcare team led by Jami Rubin notes that 2012 will be exceptional for these industries, given the numerous patent expirations.
It is calculated that large companies will earn double-digit revenue growth, equal to +18% on average. However, the US business appears to be rapidly maturing due to fewer generics coming to market first. In other words, Goldman Sachs assures, as 'designer' companies fare, so will 'generic' ones a few years later. And post-2013 remains an unknown factor for the sector, given that the potential 'drivers' of future growth are those that raise the most uncertainty, such as biosimilars and generics outside the USA.
The banking giant also welcomes the expansion of Teva, the world's leading generics maker, into the world of branded medicines, including its recent hiring of Bristol-Myers Squibb 'veteran' Jeremy Levin as CEO, as well as its biosimilars partnerships with Watson and Amgen.
Barbara Di Chiara – February 1, 2012 – PharmaKronos
Up to +30% sale of seasonal medicines in pharmacies
Freezing week ahead and we run for cover
The cold seems to have really arrived and the effects are immediately starting to be seen. Sales of me are booming in Italian pharmacies
